Stem cell technologies: regulation, patents and problems.
Human embryonic stem cell research promises to deliver in the future a whole range of therapeutic treatments, but currently governments in different jurisdictions must try to regulate this burgeoning area. Part of the problem has been, and continues to be, polarised community opinion on the use of human embryonic stem cells for research. This article compares the approaches of the Australian, United Kingdom and United States governments in regulating human embryonic stem cell research. To date, these governments have approached the issue through implementing legislation or policy to control research. Similarly, the three jurisdictions have viewed the patentability of human embryonic stem cell technologies in their own ways with different policies being adopted by the three patent offices. This article examines these different approaches and discusses the inevitable concerns that have been raised due to the lack of a universal approach in relation to the regulation of research; the patenting of stem cell technologies; and the effects patents granted are having on further human embryonic stem cell research.
Then
Shih-Ning
SN
Court of Appeal, Queensland. snthen@iinet.net.au
D001315:Australia; D001709:Biotechnology / Q000331:legislation & jurisprudence*; D019976:Cloning, Organism / Q000331:legislation & jurisprudence; D033041:Embryo Research; D006801:Humans; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D013234:Stem Cells; D006113:United Kingdom; D014481:United States